Acquisition Opportunity Healix was acquired by Singlepoint Healthcare in June 2026, signaling potential for channel synergy, integration of infusion operations, and expanded payer networks. Sales teams should explore continuity planning, cross-sell of infusion services to Singlepoint’s portfolio, and leverage combined reach to hospital systems and physician practices.

Expansion Footprint With managed infusion centers nationwide and a corporate base in Sugar Land, Texas, Healix presents a scalable platform for geographic market entry, enrollment of new physician practices, and growth of outpatient infusion offerings in underserved regions through partnership or joint venture models.

Strategic Tech Healix has invested in partnerships and software for infusion workflow optimization and enterprise IT growth, including WeInfuse and DoseMe in prior years, and uses Microsoft Azure and security tooling. Opportunities exist to upsell advanced dosing, compliance, and data analytics solutions to enhance outpatient infusion efficiency and patient outcomes.

Financial Signals Current revenue range of $50M to $100M and a leadership position in physician office-based infusion indicate a solid mid-market profile with potential for upsell of high-margin services, ongoing corporate procurement contracts, and equipment or supply modernization deals for infusion centers.

Strategic Partnerships Longstanding collaborations with software and dosing partners historically—WeInfuse and DoseMe—suggest a receptive environment for new partnerships, digital workflow enhancements, and data integration projects with pharmaceutical companies, academic medical centers, and outpatient networks seeking standardized infusion care.